CA125监测进展期卵巢癌疗效和复发的意义  

Significance of Serum CA125 in Monitoring Efficiency and Recurrence of Advanced Overian Cancer

作　　者：宋现让[1] 王少平[1] 刘美芹[1] 王爱兰[1] 朱传金[1] 丁艳涛[1] 董秀梅[1] 

机构地区：[1]山东省肿瘤防治研究院,山东济南250117

出　　处：《现代诊断与治疗》2001年第2期71-73,共3页Modern Diagnosis and Treatment

摘　　要：目的　评估CA12 5监测进展期卵巢癌疗效及复发的应用价值。方法　采用ES3 0 0全自动酶免疫分析系统检测 5 4例Ⅲ、Ⅳ期原发卵巢癌患者、42例综合治疗后随访卵巢癌患者、2 4例治疗后复发或远处转移患者、15例卵巢良性肿瘤和65例健康女性血清CA12 5水平。结果　 ( 1) 5 4例进展期原发卵巢癌患者血清CA12 5水平显著高于正常人和卵巢良性肿瘤患者。以 3 5U/ml为限定值 ,卵巢上皮癌 10 0 %阳性 ,非上皮癌中 2例内胚窦瘤为阴性 ,其余均阳性。良性肿瘤 13 .3 %假阳性。Ⅲ、Ⅳ期间无显著差异。 ( 2 )原发卵巢癌患者经综合治疗后 ,CA12 5明显下降 ,病情转归与CA12 5下降的幅度相关 ,但与治疗前水平无关。 ( 3 ) 42例随访未出现复发者 ,10 2次检测CA12 5平均值为 2 7.85± 12 .66U /ml ,连续 2次CA12 5升高者 2例 ,治疗后复发或远处转移者 2 4例 ,CA12 5平均值为 3 3 9.5 5± 2 46.6U/ml,其中 95 .8% ( 2 3 /2 4)高于限定值。CA12 5判断复发的准确率为 95 .4% ( 63 /66)。结论　CA12 5的连续监测可作为进展期卵巢癌疗效评价、复发转移及预后的一个有用指标。Objective To evaluate the value of serum CA125 as a marker in monitoring efficiency and recurrence of advanced ovarian cancer.Method ES300 automatic enzyme immune analysis system was used to detect the levels of serum CA125 in 54 stages Ⅲ and Ⅳ primary ovarian cancer patients,42 follow up ovarian cancer patients,24 recurrent or metastatic patients,15 cases of benign ovarian tumors and 65 healthy control women.Results (1)Pretreatment Serum CA125 levels in 54 advanced ovarian cancer patients were significantly higher than those in control group and ovarian benign tumors.Put 35 U/ml as critical value,CA125 levels were elevated in 100%(43/43) of epithelial ovarian cancer,and in 81.8%(9/11) of non epithelial ovarian cancer.There was no significant difference between stages Ⅲ and Ⅳ.(2)Serum CA125 levels decreased sharply after comprehensive therapy.The course of disease significantly correlated with the decrease range of serum CA125 after treatment,but did not correlate with the level before treatment.(3)In 42 follow up patients without recurrence,102 times serum CA125 detection were carried out,there are only 2 patients whose serum CA125 increased in two series assays.Otherwise,serum CA125 increased over 35U/ml in 23/24(95.8%) of patients with recurrent or metastatic diseases.Diagnosis rate of CA125 for recurrent or metastatic diseases were up to 95.4(63/66).Conclusions Series detection of serum CA125 is a useful index for evaluation of efficiency,recurrence,metastasis and prognosis.

关 键 词：卵巢肿瘤 CA125抗原 肿瘤标记物 肿瘤复发 监测 

分 类 号：R737.31[医药卫生—肿瘤]